Joseph G. Pressey · Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
Follow
Article1 min read·Published Jan 2023Older

Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jan 2023 · 1 min read

In brief

In brief

This phase 3 randomized controlled trial demonstrates that nirogacestat, an oral γ-secretase inhibitor, significantly improves progression-free survival in adults with progressing desmoid tumors compared to placebo (76% vs 44% event-free at 2 years). The drug also achieved higher objective response rates (41% vs 8%) and improved patient-reported outcomes including pain and physical functioning.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Background: Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments. Methods: We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat (150 mg) or placebo twice daily. The primary end point was progression-free survival. Results: From May 2019 through August 2020, a total of 70 patients were assigned to receive nirogacestat and 72 to receive placebo. Nirogacestat had a significant progression-free survival benefit over placebo (hazard ratio for disease progression or death, 0.29; 95% confidence interval, 0.15 to 0.55; P<0.001); the likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo. Between-group differences in progression-free survival were consistent across prespecified subgroups. The percentage of patients who had an objective response was significantly higher with nirogacestat than with placebo (41% vs. 8%; P<0.001), with a median time to response of 5.6 months and 11.1 months, respectively; the percentage of patients with a complete response was 7% and 0%, respectively. Significant between-group differences in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related

Statements in this article

  1. Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.

    EstablishedBackground
  2. Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat at 150 mg or placebo twice daily.

    RecommendationMethods
  3. Nirogacestat had a significant progression-free survival benefit over placebo with a hazard ratio for disease progression or death of 0.29 (95% confidence interval, 0.15 to 0.55; P<0.001).

    ResearchResults
  4. The likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo.

    ResearchResults
  5. The percentage of patients who had an objective response was significantly higher with nirogacestat than with placebo (41% vs. 8%; P<0.001).

    ResearchResults
  6. The median time to response was 5.6 months with nirogacestat and 11.1 months with placebo.

    ResearchResults
  7. The percentage of patients with a complete response was 7% with nirogacestat and 0% with placebo.

    ResearchResults
  8. Significant between-group differences were observed in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life.

    ResearchResults

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.